Osiris Therapeutics Concludes Successful Defense of Stem Cell Patent Challenge in Australia
Osiris Therapeutics (NASDAQ: OSIR) announced today the successful conclusion of a patent
challenge in Australia by an opponent whose identity under Australian
law was not disclosed. The patent at issue covers the administration of
mesenchymal stem cells (MSCs), including Prochymal® (remestemcel-L),
for the treatment of inflammatory conditions involving the
gastrointestinal tract, including Crohn's disease and ulcerative colitis.
As acknowledged in the Australian Official Journal of Patents
Supplement, all claims to the patent will be maintained in full. The
claims specifically include the use of allogeneic MSCs, an attribute
central to making an off-the-shelf MSC product possible.